Drug intelligence / Profile preview

86C

Development stage: Preclinical
Lead developer: University of Texas MD Anderson Cancer Center
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Parenteral

Overview

86C is a monoclonal antibody that specifically targets cell surface vimentin (CSV), a protein marker found on the surface of glioma stem cells (GSCs) but absent from normal cells. Developed by researchers at the M.D. Anderson Cancer Center, 86C is designed to overcome chemoresistance in glioblastoma multiforme (GBM). The antibody works by binding to CSV, which sensitizes GSCs to temozolomide (TMZ)-mediated cell death. Preclinical evidence suggests that 86C can reverse resistance in GSCs, particularly in those with high CSV expression or rapid resurfacing rates, potentially offering a new strategy for treating aggressive brain tumors.

Other names: anti-CSV antibodyanti-cell surface vimentin antibody

Targets

VIM (Vimentin)

Beyond the preview

Go deeper on 86C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 86C.

Explore the full profile